Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819284 | 0.98 | SMN1; SMN2 (0.31) | SMN1; SMN2MAPK1HSD17B10 | |
| SCHEMBL820220 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL1178810 | 0.67 | — | — | |
| SCHEMBL1046898 | 0.65 | — | — | |
| SCHEMBL1178759 | 0.65 | ALDH1A1 (0.30) | — | |
| SCHEMBL469272 | 0.61 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPK1HSD17B10 | |
| Bromide SCHEMBL588925 | 0.59 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPK1HSD17B10 | |
| Bromide SCHEMBL28328295 | 0.59 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPK1HSD17B10 | |
| Water SCHEMBL28160101 | 0.59 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL739942 | 0.59 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2574187-B1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | AMYRIS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-8586814-B2 | Squalane and isosqualane compositions and methods for preparing the same | Amyris, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130109884-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-05-02 | — | — | US | disclosed |
| EP-2585427-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | Sumitomo Chemical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2574187-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Amyris Biotechnologies, Inc. (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-03-21 | — | — | US | disclosed |
| WO-2012176930-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-12-27 | — | — | WO | disclosed |
| WO-2011162404-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011146837-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | Amyris, Inc. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110287988-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | EUAGORE, LLC | 2011-11-24 | — | — | US | disclosed |
| US-7964758-B2 | Process for production of 2-(substituted phenyl)-3,3,3-trifluoropropene compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100160683-A1 | Process for Production of 2-(Substituted Phenyl)-3,3,3-Trifluoropropene Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287988-A1 | SQUALANE AND ISOSQUALANE COMPOSITIONS AND METHODS FOR PREPARING THE SAME | SQLE, FDFT1, COASY | SMN1; SMN2 2616/4885MAPK1 4680/4885HSD17B10 44/4885 |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MGMT, BBOX1 | SMN1; SMN2 3007/4885MAPK1 2909/4885HSD17B10 370/4885 |
| US-20130109884-A1 | PROCESS FOR PRODUCING ALPHA-KETOCARBOXYLIC ACID | ALDH18A1, MCCC2, ALDH7A1 | SMN1; SMN2 4535/4885MAPK1 1580/4885HSD17B10 104/4885 |
| US-20100160683-A1 | Process for Production of 2-(Substituted Phenyl)-3,3,3-Trifluoropropene Compound | PEX3, SCO2, LPO | SMN1; SMN2 2168/4885MAPK1 320/4885HSD17B10 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.